Furthermore, several experimental facts have shown that ALKBH5 is associated with the malignant transformation of cancer [28–34], indicating that ALKBH5 inhibitors can be a target of tumor-agnostic therapy. The gene discussed is ALKBH5; the disease is neoplasm.